BRIEF-Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia

July 21 (Reuters) - Kyowa Kirin Co Ltd 4151.T:

  • EUROPEAN COMMISSION APPROVES CRYSVITA® (BUROSUMAB) FOR INFANTS WITH X-LINKED HYPOPHOSPHATAEMIA IN THE EUROPEAN UNION

  • KYOWA KIRIN CO - CRYSVITA GRANTED TWO-YEAR EXTENSION OF ORPHAN MARKET EXCLUSIVITY IN EU TO FEBRUARY 2030

Source text: ID:nBw8trhyma

Further company coverage: 4151.T


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.